Summary
On October 27th, 2026, Anthropic announced it had acquired Mythril Medicine, a one-person company developing treatments for two rare forms of muscular dystrophy. Founder Cody Tranbarger used Claude to manage contracts, logistics, and experiments across 11 outside labs, taking a possible treatment from idea to a promising result in mice in under 18 months. He now works at Anthropic, which expects one of his drug candidates could be ready for human trials as soon as late 2028.
The video walks through Anthropic’s report, “Early Progress on Accelerating Drug Development with Claude,” which describes work with six drug-development organizations. Examples include Generate Biomedicines using Claude Code to design a CAR T-cell component about 70% shorter than the standard version, Divergence Labs generating 35,000 antibody designs for food allergies in about a month, and Big Hat Biosciences testing more than a thousand antibody variants in 10 weeks. Other cases cover manufacturing documentation review at Invida, where Claude caught all 11 issues human reviewers found plus seven more, and clinical trial planning at Bristol Myers Squibb.
David Shapiro then connects these results to personalized medicine, citing the case of KJ Muldoon’s custom gene-editing therapy, and argues that the bottleneck is expert capacity, which is why he believes far more compute is needed to reach longevity escape velocity. The report itself notes the research is still early and mostly pre-human trials.
📺 Source: David Shapiro · Published November 02, 2026
🏷️ Format: News Analysis
